Vapotherm Blog

Could Your Hospital Save Money? The Economic Benefits of Ambulation

The medical community widely recognizes that prolonged bedrest can have harmful effects on patients while early mobility can lead to better outcomes. Yet, deep sedation of mechanically ventilated patients,  and prolonged bed rest remain frequent practices in many ICUs. Mobilization goals can be difficult to achieve, because establishing mobility programs requires multi-disciplinary teams, education, concerted

How to Treat Respiratory Distress in Acute Decompensated Heart Failure Patients Without Using a Mask?

When it comes to treating patients with acute decompensated heart failure (ADHF), usually an exacerbation of congestive heart failure (CHF), non-invasive positive pressure ventilation (NiPPV) is often the go-to therapy. However, studies show that more than 30% of patients cannot tolerate NiPPV due to mask intolerance.1 There is a multitude of strategies clinicians can employ

Subgroup Analysis Suggests HVNI Non-Inferior to NiPPV in Treatment of Acute Decompensated Heart Failure Patients

In March 2019, Haywood and colleagues published the results of a subgroup analysis in the American Journal of Emergency Medicine titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED.” The analysis examined the acute decompensated heart failure (ADHF) sub-population of a multi-center, randomized,

What Spectrum of Patients Can Go On Hi-VNI® Technology?—An Emergency Physician Discusses

Vapotherm’s Hi-VNI® Technology is a tool for can treating respiratory distress. Vapotherm does not practice medicine or provide medical services or advice, any clinical recommendations provided herein are solely those of the speakers. Practitioners should refer to the full indications for use and operating instructions of any products referenced before use. Hi-VNI Technology is Mask-Free

Mask-Free NIV™ for Spontaneously Breathing Patients in the Emergency Department—ED Doctors Discuss Their Experience

Vapotherm’s Hi-VNI® Technology is a tool for can treating respiratory distress.  Vapotherm does not practice medicine or provide medical services or advice, any clinical recommendations provided herein are solely those of the speakers. Practitioners should refer to the full indications for use and operating instructions of any products referenced before use. All participants are paid

A Moving Moment with the Vapotherm® Transfer Unit

Being confined to an ICU bed is hard for many patients for even a couple of weeks, let alone for over one hundred days. Patient ambulation not only has the benefit of counteracting the harmful effects of prolonged bedrest1, but it can improve patient mood.2 Watch the story of one such ICU patient. Learn more

Imagine the Ventilatory Support of NiPPV with the Comfort of Humidified High Flow

Clinicians admitting patients in respiratory distress traditionally have three categories of tools to relieve symptoms. There is oxygen therapy for low severity patients, non-invasive positive pressure ventilation (NiPPV) for moderate distress, and then mechanical ventilation for severe cases of respiratory distress. Thanks to Hi-VNI® Technology, clinicians now have a new tool to treat a broad

The Seven Types of Patients That Could Benefit from High Velocity Therapy

High Velocity Therapy delivered with Hi-VNI® Technology is mask-free noninvasive ventilation (NIV) for spontaneously breathing patients. It is a viable alternative to NiPPV and can relieve undifferentiated respiratory distress, including hypercapnia and hypoxemia.11. Doshi, Pratik et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Annals of Emergency Medicine, 2018.

Treating the Congested Patient with High Velocity Nasal Insufflation

Whether it’s pneumonia, bronchiolitis, or other respiratory infections, secretion clearance is one of the keys to symptom relief. Rehydration of airway mucosa to promote mucociliary function helps with secretion clearance, and this can be effectively achieved by inhalation of heated, humidified gas.11. Williams R, Rankin N, Smith T, Galler D, Seakins P. “Relationship between the

Study Shows Clinicians Using Vapotherm® Oxygen Assist Module Prototype Significantly Better at Achieving Target SpO2 in NICU than Manual Titration

In November 2018, the Archives of Disease in Childhood: Fetal & Neonatal edition published the results of a prospective, two-center, order-randomized cross-over study performed at two NICUs in the UK, designed to evaluate the performance of Vapotherm®’s forthcoming Oxygen Assist Module (OAM) technology. OAM is a module for the Precision Flow® system, designed to be used